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Background: Neurodegenerative dementia comprises chronic and progressive illnesses with major clinical features
represented by progressive and permanent loss of cognitive and mental performance, including impairment of
memory and brain functions. Many different forms of neurodegenerative dementia exist, but they are all
characterized by death of specific subpopulation of neurons and accumulation of proteins in the brain. We
incorporated data from OMIM and primary molecular targets of drugs in the different phases of the drug discovery
process to try to reveal possible hidden mechanism in neurodegenerative dementia. In the present study, a systems
biology approach was used to investigate the molecular connections among seemingly distinct complex diseases
with the shared clinical symptoms of dementia that could suggest related disease mechanisms.
Results: Network analysis was applied to characterize an interaction network of disease proteins and drug targets,
revealing a major role of metabolism and, predominantly, of autophagy process in dementia and, particularly, in
tauopathies. Different phases of the autophagy molecular pathway appear to be implicated in the individual
disease pathophysiology and specific drug targets associated to autophagy modulation could be considered for
pharmacological intervention. In particular, in view of their centrality and of the direct association to autophagy
proteins in the network, PP2A subunits could be suggested as a suitable molecular target for the development of
novel drugs.
Conclusion: The present systems biology investigation identifies the autophagy pathway as a central dis-regulated
process in neurodegenerative dementia with a prevalent involvement in diseases characterized by tau inclusion and
indicates the disease-specific molecules in the pathway that could be considered for therapy.
Keywords: GSK-3β, AMPK, Frontotemporal dementia, Alzheimer’s disease, Lewy bodies disease, Progressive
supranuclear palsy, Corticobasal dementia, Pick’s disease, Amyotrophic lateral sclerosis-Parkinsonism/dementia
complexBackground
Dementia is a clinical syndrome that characterizes many
different etiologies, including neurodegenerative, meta-
bolic, vascular, and infectious diseases defined by a cluster
of symptoms and signs manifested by difficulties in me-
mory, disturbances in language, psychological and psy-
chiatric alterations, and impairments in daily living
activities. The neurodegenerative dementias can be caused
by a multiplicity of conditions or diseases that lead to the* Correspondence: caberlotto@cosbi.eu
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article, unless otherwise stated.progressive and irreversible degeneration of specific popu-
lations of neurons and their connections. The most com-
mon cause of neurodegenerative dementia is Alzheimer's
disease, less frequent causes include, among other, Lewy
body dementia, frontotemporal dementia, and Prion
disease.
Individual neurodegenerative dementia diseases are
characterized histologically by varying grades of neuronal
loss, gliosis, and abnormal accumulation of proteins. The
nature of protein deposition defines the histological classi-
fication of each neurodegenerative dementia in two major
groups: tauopathies and synucleinopathies, associated with
the pathological aggregation of tau or alpha-synucleined Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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global prevalence, the precise neurobiological basis and
terms for objective diagnosis of neurodegenerative demen-
tias remain controversial, and comprehensive understan-
ding of the neurobiology basis of the diseases remains
lacking. Moreover, heterogeneous clinical presentations of
the same molecular pathology, comorbidity or unexpected
pathologies which characterize the aging brain and a
strong clinical and pathological overlap between dis-
tinct neuropathological diagnoses render insights in the
different disorders extremely important for diagnostic
purposes.
The molecular background of the phenotypic variability
in neurodegenerative dementia has been investigated and
a spectrum of relations between clinical syndromes and
molecular features has been identified. Although some
proteins have emerged as important players in the me-
chanism of neurodegeneration, the precise molecular ma-
chinery involved in neurodegeneration remains largely
unknown.
Systems biology has been paving the way to the explo-
ration of complex associations of diseases and, thus, to the
inference of the pathogenic mechanism of a particular
disease by considering disease-related components in a
large-scale network [3-5]. Although systems biology ap-
proach could be limited by its deterministic view of genes
as influencing various phenotypes, and by the lack of
appreciation of physiological regulation and of cultural
and environmental aspects, it could, however, give advan-
tages over the narrow view of what constitutes ‘traditional
biology’. Molecular networks, particularly protein-protein
interaction networks (PIN), are extraordinarily informative
because it is well-known that most cellular components
do not solely perform the biological functionality, but
interplay with other cellular components in an intricate
interaction network [4-8]. Human PIN has been a valuable
data resource to study molecular pathogenesis for a wide
range of diseases [6-13]. Among those, numerous studies
have been carried out to deeply understand the molecular
networks related to neurodegenerative diseases (NDs),
proposing different methodological approaches including
network analysis to study Alzheimer’s disease based on
PIN and data integration [14], inference of overlapping
regulators of NDs in different organisms [15], pathway-
based method to uncover the direct commonality among
NDs [16], or reconstruction of NDs network based on PPI
networks, regulatory networks, and Boolean networks
[17]. In addition to disease genes study, systems biology
approach has been also applied to drug target elucidation
[18]. Yu et al. proposed a systematic approach that used of
Random Forest and Support Vector Machine for pre-
dicting drug targets by combining the chemical, genomic,
and pharmacological information [19]. In Emig et al. [20],
a disease gene expression signature and a high-qualityinteraction network were integrated using network-based
approach to prioritize the list of drug targets. Thus, sys-
tems biology application in pharmacology hold promises
for drug discovery.
The aim of the present study was to identify key molecu-
lar hubs relevant for neurodegenerative dementia using a
network-based approach in a context of protein-protein
interaction. The diseases studied were: Frontotemporal de-
mentia (FTD), Alzheimer disease (AD), Lewy bodies disease
(LBD), Progressive supranuclear palsy (PSP), Corticobasal
dementia (CBD), Pick’s disease, Prion disease, Hungtington’s
disease and Amyotrophic lateral sclerosis-Parkinsonism/
dementia complex. Both Tauopathies and synucleinopa-
thies were included to try to uncover any molecular altera-
tion characterizing these subgroups of dementia-related
diseases. This is the first attempt of application of systems
biology methodology to reveal the molecular complexity
of this subgroup of neurodegenerative disorders integra-
ting not only the current knowledge on the specific dis-
eases (OMIM), but also the drug targets, representing the
broadest coverage of the genes that has been considered
relevant for the treatment of dementia-associated symp-
toms. This integration of network analysis in biomedical
research has uncovered hidden molecular pathways that
are mutual between distinct diseases sharing the common
symptoms of dementia and provided further support to
the hypothesis of alteration in autophagy as the molecular
basis of these groups of neurodegenerative disorders, par-
ticularly tauopathies.
Methods
The study pipeline is presented in Figure 1 and it is com-
posed by three major steps: (1) Reconstruction of the
interaction network by integrating OMIM disease genes,
drug target genes and PIN, (2) Analysis of the interaction
network of disease genes and drug targets, and (3)
Functional annotations analysis of disease genes and drug
targets. The three steps are described in details in the fol-
lowing subsections.
Reconstructing integrating networks of disease genes and
drug targets
Three datasets were used to construct the network:
OMIM disease genes, drug target genes and protein
interaction network.
OMIM disease seed genes
Disease genes and genetic phenotypes of the different
neurodegenerative dementia diseases (Table 1) were ex-
tracted from the OMIM database [21], a comprehensive,
authoritative compendium of human genes and genetic
phenotypes [22]. Keywords that are most relevant for
the disorders were defined, such as the official disease
names and alternative names. A text mining process was
Figure 1 Schematic representation of the network analysis workflow. Seed genes provide information on neurodegenerative dementia
diseases-associated genes in the OMIM database and on primary molecular drug targets in the different phases of the drug discovery process.
Following reconstruction of the protein-protein interaction (PPI) network derived from the integration of seed genes (disease genes and drug
targets) and I2D database, we characterized the functional enrichment of the protein in the network by testing over-represented Gene Ontology
biological process terms.
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words in the OMIM database.
Drug target seed genes
Drug molecular targets were obtained by collecting infor-
mation from different pharmaceutical company websites,
from a clinical trial database (www.clinicaltrial.gov) and
from the Drug Bank (www.drugbank.ca) (Additional file 1:
Table S1). Drugs for the treatment of dementia in all
phases of the drug discovery process, from preclinical to
marketed drugs, were included. This approach allowed
obtaining the broadest coverage of the genes of interest
for pharmaceutical drug development to identify the over-
all key molecular targets of interest for the treatment of
dementia. Only primary targets were considered as seed
genes for network analysis.
Protein-protein interaction network
The protein interaction network integrating dementia
genes and drug target was extracted from the Interologous
Interaction Database (i2d) [23], which is an integrated
database of the majority of all known experimental and
predicted human protein interaction data sets (including
HRPD, BIND, BioGrid, etc.). The database consisted of
846,116 interactions in total, with 173,338 homo sapiens-
related. To construct a PIN related to dementia, we firstly
extracted the corresponding product proteins of the seed
genes (diseases and drug target). We used the ID mappingscheme provided by the Uniprot database to map the seed
gene symbols to the Uniprot protein accessions. Conse-
quently, two sets of proteins were obtained, the set of dis-
ease proteins SDG corresponding to the OMIM disease
seed genes, and the set of drug target proteins SDT corre-
sponding to drug target seed genes. Based on these two
sets SDG and SDT, we then extracted PIN by processing
raw data of protein-protein interactions (PPI) in the i2d
database. All the homologous predicted protein inte-
ractions in the i2d database were excluded to increase the
reliability of the protein interaction data. The final inter-
action network contained the nodes representing disease
proteins and drug targets, and the edges representing their
protein interactions (Figure 2). We took into account only
direct interactions (i.e., one-step neighbors). The network
was undirected and unweighted because we considered
the binary interactions.
Network analysis
To gain information on the network and their participa-
ting proteins, we evaluated the centrality of proteins in the
network. In view of the fact that the functional importance
of proteins might be inferred from their central roles in
the network [24-26], we computed the degree index for
each protein, one of the most applied indices to evaluate
the centrality in the network.
A graph G(E,V) consists of a set of vertices (V) and a
set of edges (E) between them. An edge eij connects
Table 1 Neurodegenerative dementia diseases with their
relative disease proteins and protein marker
Disease Disease
protein
Official
gene
symbol
Protein
marker
Alzheimer P05067 APP Tau
Alzheimer P01023 A2M Tau
Alzheimer P49768 PSEN1 Tau
Alzheimer Q6ZW49 PAXIP1 Tau
Alzheimer P49810 PSEN2 Tau
Alzheimer P29474 NOS3 Tau
Alzheimer P05164 MPO Tau
Alzheimer Q92870 APBB2 Tau
Alzheimer P02649 APOE Tau
Alzheimer P00749 PLAU Tau
Alzheimer Q30201 HFE Tau
Alzheimer Q92673 SORL1 Tau
Alzheimer P12821 ACE Tau
Alzheimer Q13867 BLMH Tau
Amyotrophic lateral
sclerosis-Parkinsonism/
Dementia complex
Q99497 PARK7 Tau
Dementia, familial,
non-specific
Q9UQN3 CHMP2B Tau
Dystonia-Parkinsonism P21675 TAF1 Tau
Frontotemporal Dementia Q13148 TARDBP Tau
Frontotemporal Dementia P10636 MAPT Tau
Frontotemporal Dementia P28799 GRN Tau
Supranuclear palsy P10636 MAPT Tau
Prion P04156 PRNP Prion
Prion P54259 ATN1 Prion
Prion Q99574 SERPINI1 Prion
Prion P01920 HLA-DQB1 Prion
Prion, Huntington disease-like 1 P04156 PRNP Prion/
Hungtintin
Huntington Disease P42858 HTT Hungtintin
Huntington disease-like 1 P04156 PRNP Hungtintin
Huntington disease-like 2 Q8WXH2 JPH3 Hungtintin
Huntington disease-like-4 P20226 TPB Hungtintin
Dementia, Lewy body P37840 SNCA Alpha-synuclein
Dementia, Lewy body Q16143 SNCB Alpha-synuclein
List of neurodegenerative dementia disease, proteins (Uniprot ID) associated
to the disease as obtained from OMIM database and relative Official Gene
Symbol and protein markers related to the diseases.
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vestigated since our studied protein interaction networks
are undirected. An undirected graph has the property
that eij and eji are considered identical. Therefore, theneighbourhood Ni for a vertex vi is defined as its direct
connected neighbours by Equation (1):
Ni ¼ vj : eij∈E
  ð1Þ
The degree Di of a vertex is defined as the number of
vertices |Ni|, in its neighbourhood Ni.
We then computed different network measures to
comprehend the topological properties of the con-
structed network (Table 2).
 Number of connected components: A connected
component is a group of all nodes that are pairwise
connected. The number of connected components
indicates the connectivity of a network – a lower
number of connected components suggest a
stronger connectivity.
 Measures to shortest paths: The length of a path is
the number of edges forming it. There may be
multiple paths connecting two given nodes. The
shortest path length, also called distance, between
two nodes n and m is denoted by L (n,m).
 Network diameter: the largest distance between
two nodes. If a network is disconnected, its
diameter is the maximum of all diameters of its
connected components.
 Network radius: the smallest distance between
two nodes
 Average shortest path length: also known as the
characteristic path length, gives the expected
distance between two connected nodes
 Average number of neighbors: indicates the average
connectivity of a node in the network
 Network density: a normalized value of the average
number of neighbors
 Network centralization: a simple and widely used
index of the connectivity distribution. Networks
whose topologies resemble a star have a
centralization close to 1, whereas decentralized
networks are characterized by having a
centralization close to 0
 Network heterogeneity: reflects the tendency of a
network to contain hub nodes
 Clustering coefficients: In undirected networks, the
clustering coefficient Cn of a node n is defined as
Cn = 2en/(kn(kn-1)), where kn is the number of
neighbors of n and en is the number of connected
pairs between all neighbors of n. The clustering
coefficient is a ratio N / M, where N is the number
of edges between the neighbors of n, and M is the
maximum number of edges that could possibly exist
between the neighbors of n. The network clustering
coefficient is the average of the clustering
coefficients for all nodes in the network.
DISEASE 
PROTEINS
DRUG TARGETS
MEDIATOR
Figure 2 Overview of the PPI network created using disease and drug targets seed proteins and showing their common/shared direct
interacting proteins (mediators).
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mentias, we determined mediator proteins, which are
defined as proteins that have direct interactions with
both proteins in the set of SDG and of SDT. First, based
on the PIN extracted, we searched the direct neighbours
vj of all proteins vi where vj ∈ SDG, denoted IDG = {vj}.
Similarly, we obtained the set IDT = {vk}, where vk is
direct neighbours of proteins vi and vi ∈ SDT. Then the
set of mediator proteins is the intersection set of the two
sets IDG and IDT, denoted M by Equation (2).
M ¼ IDG∩IDT ð2ÞTable 2 Network measures calculated for the integrated
network
Statistics measures Value
Number of connected components 6
Network diameter 9
Network radius 1
Average shortest path length 3.851
Average number of neighbors 4.209
Network density 0.001
Network centralization 0.120
Network heterogeneity 3.897
Clustering coefficients 0.116
Network measures show the topological properties of the network with
different criteria. The first column is the type of measures and the second
column is the corresponding values.List of mediator proteins is shown in Additional file 1:
Table S1.
Functional annotation analysis
The complete lists of mediator proteins and the sub-list
related to tauopathies (Table 1) were used to extract the
most representative GO biological process terms (i.e., the
ones that are over-represented, but that do not refer to
most general biological processes). For identifying and
visualizing enriched GO terms, we used GOrilla and
REVIGO tools [27,28]. Hypergeometric distribution was
applied to test GO term enrichment, and a p-value thresh-
old of 0.001 was selected. The output graphs were ob-
tained from REVIGO, a web server that considers long
lists of Gene Ontology terms and summarizes them by re-
moving redundant GO terms. These terms can be vi-
sualized in semantic similarity-based scatterplots and this
graph-based visualization accurately renders the sub-
divisions and the semantic relationships in the data. Each
of the GO terms is a node in the graph, and 3% of the
strongest GO term pairwise similarities are designated as
edges in the graph (Figures 3, 4, and Additional file 2:
Figure S2).
In depth analysis of specific GO terms-associated genes
was performed. In particular, among the metabolic-related
GO terms indicated by the functional enrichment analysis
of the complete list of mediators and of the tauopathies-
associated sub-list (Figures 3 and 4), autophagy was se-
lected for further analysis. Thus, the proteins list related
to GO terms associated to autophagy (GO:0010506 and
Immune response
& 
Inflammation
Cell surface receptor 
signaling pathway
Metabolic Process
Figure 3 Summary of statistically significant Gene Ontology biological processes functional annotation corresponding to proteins in
the mediator list as obtained from REVIGO [28]. Nodes are GO terms and edges represent the strongest GO terms pairwise similarity. Colors
represent the p-values (low values in green, high in red). Only significant GO terms are shown (P < 0.001).
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in addition, for a complete coverage of the autophagy asso-
ciated genes in the mediator list, other mediator proteins
that have been demonstrated to be involved in autophagy
process as described in Uniprot (keyword: autophagy) were
included in the analysis. In addition to the GO-enrichment
analysis, we explored the human autophagy network [29]
to investigate the centrality of our mediators in the context
of an experimentally validated human autophagy network
[29]. Behrends et al. used a modified version of the Com-
parative Proteomics Analysis Software Suite to identify
the autophagy interaction network (AIN) of 409 non-
redundant high-confidence candidate interaction proteins
(HCIPs), making 751 interactions. They then employed
hierarchical clustering in AIN to model ten functional sub-
networks. We carried out two different analyses, first on
the complete AIN and, second, on the functional clustered
network. Firstly we computed the intersection of the medi-
ator list obtained by our method and the list of interacting
proteins in the complete AIN, to study the coverage and
the topological roles of the mediators. The degree cen-
trality and articulation position were calculated for all
mediators based on the AIN. A node is considered an
articulation point (or cut vertex) if, and only if, by remo-
ving it (and edges through it) we disconnect the graph.
Subsequently, to discover the functional roles of mediators
related to autophagy, we compared the mediator list withthe list of 32 primary baits and 33 secondary baits in
the functional sub-networks described in Behrends et al.
paper [29].
Results
We obtained the integrated network consisting of 3,450
proteins and 7,367 interactions. Table 2 shows the sta-
tistics of the integrated network. There are 6 connected
components and, among them, there exists a giant com-
ponent (the largest connected components) consisting of
3,435 proteins (99.57% of the total number of proteins)
and 7,251 interactions (98.43% of the total number of in-
teractions). Thus, the network is well-connected and
comprehensive for network analysis. The shortest path
length and neighborhood measures showed that the net-
work is centralized in a number of hubs, and proteins in
the network are close to each other and easily reached
through short paths. Using the degree index, highly-
ranked proteins were extracted as shown in Table 3. The
functional annotation analysis of the highly ranked pro-
teins revealed a predominant role of metabolic processes
including regulation of energy homeostasis, glucose
and lipid metabolism (Additional file 2: Figure S2 and
Additional file 1: Table S1). The proteins associated to
these metabolic-related GO terms are mainly AMPK
subunits (PRKAA1 and PRKAA2) and NF-kB. Cell re-
ceptor signaling pathways with terms associate to TRK
Immune response
& 
Inflammation
Metabolic Process
Cell surface receptor 
signaling pathwayCognition
Cell death
Figure 4 Representation of statistically significant Gene Ontology biological processes functional annotation corresponding to
proteins in the mediator list corresponding to neurodegenerative dementia diseases characterized by tau inclusions as obtained from
REVIGO [28]. Nodes are GO terms and edges represent the strongest GO terms pairwise similarity. Colors represent the p-values (low values in
green, high in red). Only significant GO terms are shown (P < 0.001).
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cantly enriched (Additional file 1: Table S1).
Functional enrichment analyses of GO biological
process terms were also performed for the complete list of
mediators, showing metabolic related terms, immune
response and inflammatory processes, and cell surface re-
ceptor signaling pathways (Figure 3 and Additional file 1:
Table S1). Considering mediator protein associated to
Tauopathies, similar functional annotations were pre-
sented with the addition of terms related to cell death and
cognition-related terms, such as synaptic transmission
and learning and memory (Figure 4 and Additional file 1:
Table S1). Based on the increasing interest of the role of
metabolism in dementia, a major focus was dedicated to
the metabolic processes associated terms, in particular to
autophagy. As described in Table 4, 27 mediators are in-
volved in autophagy processes or in the regulation of
autophagy.The disease genes associated to the autophagy media-
tors are shown in Figure 5 and listed in Table 4, while in
Figure 6, the drug targets directly associated to the
autophagy mediators are represented. A prevalence of
subunits of Protein Phosphatase 2A (PP2A), was evident
and highlighted in the figure.
By investigating the overlaps between the mediator list
obtained and the human autophagy network as described
in Behrends et al. paper [29], 45 mediators were found in
the network (Additional file 3: Table S3). Eight mediators
were found in top 10 central nodes in the network by
ranking the degree centrality. Moreover, 24/45 mediators
were the articulation nodes that are of high interest as
the important nodes to prevent network fragmentation
(Additional file 3: Table S3). The centrality and crucial
positions in the autophagy interaction network of the
mediators highlighted their relevant role in the autophagy
process (Figure 7A). By analyzing the 10 functional
Table 3 List of high-ranked proteins in the dementia network using the degree index
Uniprot ID Official gene symbol Gene name Degree index
Q13131 PRKAA1 Protein kinase, AMP-activated, alpha 1 catalytic subunit 419
P54646 PRKAA2 Protein kinase, AMP-activated, alpha 2 catalytic subunit 392
P03372 ESR1 Estrogen receptor 1 250
P19838 NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 247
Q13547 HDAC1 Histone deacetylase 1 218
Q00005 PPP2R2B Protein phosphatase 2 (formerly 2A), regulatory subunit B, beta isoform 201
P17252 PRKCA Protein kinase C, alpha 194
P49841 GSK3B Glycogen synthase kinase 3 beta 170
P06493 CDK11 Cell division cycle 2, G1 to S and G2 to M 163
P04150 NR3C1 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) 156
Q92769 HDAC2 Histone deacetylase 2 138
P05067 APP Amyloid beta (A4) precursor protein 136
P19438 TNFRSF1A Tumor necrosis factor receptor superfamily, member 1A 133
P67775 PPP2CA Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform 127
P20226 TBP TATA box binding protein 126
P24941 Cdk2 Cyclin-dependent kinase 2 125
P30153 PPP2R1A Protein phosphatase 2 (formerly 2A), regulatory subunit A, alpha isoform 121
P54259 ATN1 Atrophin 1 109
P50750 CDK9 Cyclin-dependent kinase 9 102
In bold is the mediator which is also disease proteins, having direct interactions with drug targets and other disease genes.
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proteins in the network. The autophagy-related mediator
proteins were not predominantly belonging to any of
the sub-networks described by Behrends and collabo-
rators, but they are present in almost all sub-networks
(Figure 7B). FTD-associated mediator proteins (Table 4)
were found in protein kinase network, vesicle elongation
and autophagosome assembly and vesicle nucleation auto-
phagy phases, while AD-associated proteins were seen
only in the protein kinase network, vesicle elongation and
autophagosome assembly stages (Figure 7C).
Discussion
In the present study, network analysis was used to explore
from the systems biology perspective, the molecular con-
nections among multifactorial complex diseases with the
shared clinical symptoms of dementia, which could sug-
gest related disease mechanisms. A number of diseases
were considered, both common (e.g. Alzheimer’s disease)
and rare disorders (e.g. amyotropic lateral sclerosis with
parkinsonism and dementia) that have as a common and
major symptom a progressive and permanent loss of cog-
nitive and mental performance (Table 1).
While previous systems biology studies on disease
focus on the disease gene network or drug target net-
work, separately, the method proposed in the current
study presented an integrated methodology that can takeadvantage of both these data, providing further insight
into the interactome related to dementia.
Among the most connected proteins (with more than
100 interactions in the network; Table 3) the first 2 pro-
teins in the list were PRKAA1 and PRKAA2, subunits of
AMP-regulated kinase (AMPK). AMPK is a central regu-
lator of energy homeostasis controlling neuronal main-
tenance in response to metabolic stress. Latest research
support an involvement of AMPK in Alzheimer [30,31]
and, in our previous study on Alzheimer’s disease, on a
separate set of data and with a very different systems biol-
ogy methodological approach, AMPK-related genes were
also found to be strongly associated to the disease [14].
Moreover, abnormal neuronal accumulation of activated
AMPK (pAMPK) has been described in different tauopa-
thies including PSP, AD, Pick’s disease, and CBD [32].
Thus, the present findings support once more the pro-
posed hypothesis of an alteration of metabolic functions
and energy regulation in dementia.
Considering the complete list of mediator proteins, Gene
ontology (GO) enrichment analysis confirmed a signifi-
cant involvement of metabolic signaling regulating energy
homeostasis, lipid and glucose metabolism (Figure 3).
Metabolic disturbances have been strongly associated to or
considered a predisposing factor in AD and a metabolic/
signal transduction hypothesis for AD and other tauo-
pathies has been suggested by Iqbal et al. [33]. Amongst
Table 4 Autophagy-related proteins and association with dementia disease proteins
Disease Disease protein Disease protein Mediator autophagy Mediator autophagy
Uniprot ID Official gene symbol Uniprot ID Official gene symbol
AD P02649 APOE P10636 MAPT
AD P05067 APP P00519 ABL1
AD P05067 APP P49768 PSEN1
AD P05067 APP P10636 MAPT
AD P05067 APP P07339 CTSD
AD Q13867 BLMH Q13131 PRKAA1
AD Q13867 BLMH Q9BXW4 MAP1LC3C
AD P29474 NOS3 P31749 AKT1
AD P49810 PSEN2 P49768 PSEN1
AD Q92673 SORL1 Q9H1Y0 ATG5
AD Q92673 SORL1 Q9C0C7 AMBRA1
AD Q92673 SORL1 Q13131 PRKAA1
FTD Q13148 TARDBP Q6ZNE5 ATG14/KIAA0831
FTD Q13148 TARDBP O95166 GABARAP
FTD Q13148 TARDBP P54646 PRKAA2
FTD Q13148 TARDBP Q13286 CLN3
FTD Q13148 TARDBP Q5MNZ9 WIPI1
FTD Q13148 TARDBP Q676U5 ATG16L1
FTD Q13148 TARDBP Q9BSB4 C12orf44/ATG101
FTD Q13148 TARDBP Q9H1Y0 ATG5
FTD Q13148 TARDBP Q9Y484 WDR45
FTD Q13148 TARDBP Q9Y4P8 WIPI2
FTD P49768 PSEN1 P10415 BCL2
FTD P49768 PSEN1 Q07817 BCL2L1
FTD/PSNP P10636 MAPT O60260 PARK2
FTD/PSNP P10636 MAPT P00519 ABL1
FTD/PSNP P10636 MAPT P31749 AKT1
FTD/PSNP P10636 MAPT P49768 PSEN1
FTD/PSNP P10636 MAPT Q13501 SQSTM1
ALSPD Q99497 PARK7 Q6ZNE5 ATG14/ KIAA0831
ALSPD Q99497 PARK7 Q9Y484 WDR45
ALSPD Q99497 PARK7 Q13286 CLN3
ALSPD Q99497 PARK7 Q9H1Y0 ATG5
ALSPD Q99497 PARK7 Q9Y4P8 WIPI2
ALSPD Q99497 PARK7 Q15831 STK11
ALSPD Q99497 PARK7 Q9P2Y5 UVRAG
ALSPD Q99497 PARK7 Q7Z6L1 TECPR1
LBD P37840 SNCA Q9H0R8 GABARAPL1,3/ATG8
LBD P37840 SNCA Q92934 BAD
In bold are the mediators protein which are also disease proteins.
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regulation of autophagy was highlighted (Figures 3 and 4).
Although autophagy has been known for decades, itsrelevance in neurons and glial physiology has been demon-
strated only recently [34]. Autophagy is involved in the
intracellular turnover of proteins and cell organelles
APP
HTT
ABL1
AKT1
NOS3
C12ORF44
ATG5
STK11
CLN3
UVRAG
WIPI2
GABARAP
PARK7
TECPR1
WDR45
ATG16L1
WIPI1
TARDBP
KIAA0831
APOE
MAPT
PARK2
SQSTM1
SNCA
BAD
PSEN1
BCL2
BLMH
SORL1
CTSD
AMBRA1
MAP1LC3C
PRKAA1
PRKAA2
ITM2B
GABARAPL1
PSEN2
BCL2L1
Figure 5 Neurodegenerative dementia autophagy-associated sub-network. In the network are indicated the disease proteins (different color
for the specific diseases) and the mediator proteins associated. Diamond symbols indicate disease proteins, green is related to FTD, orange to AD,
pink to ALSPD, and cyan to proteins that are both AD and FTD (see Table 4). Blue circles represent mediator protein associated to autophagy,
colored circles are the protein which are both disease and mediator proteins.
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http://www.biomedcentral.com/1752-0509/8/65[35,36] and AMPK is one of its main regulator [37]. In
neurons, it is involved in cellular homeostasis and cellular
protein clearance pathway and for the remodeling of ter-
minals in support of neuronal plasticity [38]. In glial cells,
autophagy is implicated in the elimination not only of glial
proteins, but also of those secreted by neurons, which
otherwise would accumulate in the extra-neuronal space
[39], and it is activated in astrocytes following injury [40].
Thus, it is not surprising that neurodegenerative dementia
diseases, which have been linked to the abnormal accumu-
lation of proteins and to alteration of synaptic plasticity,
have been associated to the autophagic system [41]. More-
over, a potential role of autophagy in dementia is also sug-
gested by the expression profile extracted from Mantra
(http://mantra.tigem.it/), a transcriptional response data-
base of FDA approved drugs, of 2 drugs clinically in use
for the treatment of Alzheimer’s disease: galantamineand memantine. Several genes are modulated including
AMBRA1, GABARAPL1, CLN3, SQSTM1, and AMPK
subunits.
Detailed examination of autophagy-related genes in the
mediator list, showed a preferential association to tauo-
pathies, as demonstrated also by the GO enrichment study
in the subset of mediators linked to dementia disease
characterized by Tau protein inclusions (Figure 4). Auto-
phagy process consists of several sequential steps inclu-
ding protein kinase network regulating the system, vesicle
elongation, autophagosome assembly, and vesicle nucle-
ation (Figure 7C) [29] and specific autophagy dysfunctions
could explain the diverse pathological course of the dis-
orders. Analyzing in more detail these autophagy me-
diators and the molecular link to the specific disease
genes, AD and FTD-related mediator proteins appears to
be mainly associated to the initiation complex of the
GABRG2
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Figure 6 Autophagy-associated drug target sub-network. In the network are shown the drug targets (yellow squares) and the associated
autophagy-related mediator proteins (blue circles). In red are highlighted the PP2A proteins subunits.
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http://www.biomedcentral.com/1752-0509/8/65macroautophagy cascade, involving mainly beclin 1 inter-
actome: B-cell CLL/lymphoma 2 (BCL2), BCL2-like 1
(BCL2L1), and Atg14 (Figure 6). Beclin 1 interactome
contains stimulating and suppressive components regulat-
ing the initiation of the autophagosome formation and, re-
cently, Beclin 1 has been found to be down-regulated in
AD brain. Moreover, suppression of Beclin 1 in cultured
neurons and transgenic mice induces the deposition of
amyloid-β peptides, whereas its overexpression reduces its
accumulation [42]. Beclin 1 protein also assembles two
core complexes, Atg14L or UVRAG complexes, and with
Atg14L protein induces the phagophore formation and,
thus, stimulates autophagocytosis, whereas the UVRAG/
Beclin 1 complex controls other Beclin 1-dependent
functions, e.g. phagocytosis. The subcellular compart-
mentation of Beclin 1 is regulated by different molecules
including BCL-2 [43] and mTOR [44] which arerepresented in the mediator list. Several proteins can con-
trol the activation of beclin complex including two protein
kinases included in our mediator list: CKD2 and CDK5
[45] (Additional file 1: Table S1). Atg5 protein, a mediator
related to both AD and FTD disease genes (Figures 5 and
6), is also essential for the autophagy process and, in a
conjugated form with Atg12 and Atg8 (LC3), is in-
volved in the early stages of autophagosome formation
(Figure 7C). Taken together these results suggest impair-
ment in the early stages of autophagy complex essential
for autophagosome formation [46,47], including protein
kinase network regulating autophagosome assembling.
The hypothesis that autophagy regulation and, in particu-
lar, its induction could contribute to AD pathology is also
supported by recent evidence suggesting that the synthesis
of components of the lysosome is up-regulated at the
transcriptional and translational levels in the AD brain
FTD
AD
FTD/AD
C
BA
ALSPD
Figure 7 Integration of neurodegenerative dementia mediator proteins with human autophagy network (modified from [29]). In A)
mediator proteins of the dementia network are charted in the human autophagy interaction network, in B) mediator proteins are mapped in the
human autophagy sub-networks and in C) mediator proteins are highlighted in the functional integration of the autophagy interaction network.
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http://www.biomedcentral.com/1752-0509/8/65and AD mouse models [48-54]. Moreover, Lipinski et al.
[55] recently reported an up-regulation of the trans-
cription of genes stimulating autophagy and a down-
regulation of the negative regulators of autophagy in the
brains of AD affected subjects. In the dementia network,
this interactome is connected to presenilin (Figure 5) whose
mutation underlies the majority of familial Alzheimer’s
disease cases [56-58] and whose role in autophagy has
been shown to be central [59], presenilin 1 being essen-
tial for lysosome acidification, and proteolysis during
autophagy [60].
Frontotemporal dementia-related mediator proteins
seem to be involved not only in the vesicle elongation and
autophagosome assembling process, but also, and exclu-
sively, to vesicle nucleation procedure (Figure 7C). This
process includes WIPI proteins (WD-repeat protein in-
teracting with phosphoinosides), WIPI-1 and WIPI-2,evolved from the yeast ancestral autophagy protein Atg18
(Proikas-Cezanne T, 2004; Polson HE, 2010) as membrane
components of autophagosomes (Mauthe 2011, [61]).
Both WIPI-1 and WIPI-2 specifically bind PtdIns(3)P and
localize at autophagosomal membranes (phagophore) [62].
TARDPB (TDP-43) appears to be a central protein in
our autophagy-related sub-network (Figure 5). TDP-43 is
a DNA/RNA-binding protein with multicellular functions.
Several mutations of its gene have been reported in cases
of frontotemporal lobar degeneration (FTLD) [63]. It
is processed and degraded by both autophagy and the
ubiquitin-proteasome systems [64]. Activation of auto-
phagy by rapamycin plays an active role in the clearance
of TDP-43 deficits in mouse model with proteinopathies
of the TAR DNA-binding protein 43 [65]. Depletion of
TDP-43 induces a down-regulation of the major auto-
phagy component Atg7, causes impairment of autophagy
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http://www.biomedcentral.com/1752-0509/8/65and facilitates the accumulation of polyubiquitinated pro-
teins which could be rescued by overexpression of the
protein, with a feedback regulatory loop between TDP-43
and autophagy [64]. In our network, TDP-43 is linked to
AMPK subunit PRKAA2 and a functional link between
these two proteins has been suggested in pathological con-
ditions showing that activated AMPK adversely affects
mutant TDP-43-induced motor neurons diseases [66]. In
addition, it is related to other central autophagy proteins
such as ATG5 and ATG16L, which create a multimeric
complex playing an essential role in autophagosome for-
mation, a system highly conserved in all eukaryotes [67].
The other proteins linked to TDP-43 are WIPI1 and 2
(Figure 5). Thus, these findings could suggest a thera-
peutic modulation of autophagy involving approaches that
functionally target WIPI proteins and ATG5-ATG16 com-
plex for the treatment of FTD and other diseases involving
mutations in TDP-43 gene.
Apart from the metabolic-associated biological pro-
cesses terms, cell surface receptor signaling pathway-
related terms were also highly significant enriched, in
particular in proteins associated to the Wnt pathway
(Figures 3 and 4). Several proteins in the mediator list
are represented in the pathway (see Additional file 4:
Figure S4) including GSK-3β, a tau kinase that was
also included in the most connected mediator proteins
list (Table 3) and in the autophagy-related proteins
(Additional file 3: Table S3). Several preclinical and clinical
data strongly link GSK-3β to dementia: different inhibitors
of GSK3B activity block neurodegeneration in vitro, and
GSK-3β -mediated Wnt signaling can mediate amyloid
peptide toxicity in vitro [68,69]. Finally, in human post-
mortem brain, this protein is physically associated with
neurofibrillary tangles, one of the pathologic hallmarks of
AD [70]. WNT pathway has also been recently linked to
autophagy. In fact, autophagy negatively regulates Wnt
signalling by promoting Dishevelled (Dvl) degradation,
with a role for Von Hippel–Lindau protein-mediated ubi-
quitylation [71], both of them present in the dementia net-
work mediator list.
In our dementia network, among the drug targets asso-
ciated to the autophagy-related mediators, the highest rep-
resented proteins are subunits of the Protein phosphatase
2A (PP2A; Figure 5), a serine/threonine-specific protein
phosphatase consisting of A, B and C subunits that plays
multiple roles in different signaling pathways and regu-
lates diverse cellular processes. Among the six PP2A pro-
teins, three proteins (PPP2R2B, PPP2CA, and PPP2R1A)
are also listed in the highly ranked proteins in the de-
mentia network (Table 3), demonstrating their centrality.
A recent study confirms that PP2A blockade inhibits
autophagy potentially through activation of AMPK [72]. A
role of PP2A in dementia is further demonstrated by the
evidence that okadaic acid and calyculin A, two potentPP2A inhibitors [73], are able to induce tauopathy and
cognitive deficiency in rats [74,75]. Thus, PP2A subunits
could be considered as a potential therapeutic target
for AD.
In our drug targets list related to autophagy mediators
(Figure 6), other molecular targets could be considered
suitable for therapeutic intervention including AMPK-
related proteins, a highly ranked protein in our network
(Table 3 and Additional file 3: Table S3) and a target
which has been already considered for the treatment of
Alzheimer’s disease. In fact, pioglitazone, an antidiabetic
drug which acts also by activating AMPK [76], has been
proven to reverse pathological conditions in an animal
model of the disease [77] and it is in clinical trial for
Alzheimer’s disease (www.clincaltrial.gov).
In more general terms, a direct action on the regu-
lation of autophagy, potentially an activation of the
autophagic process should be considered to the deve-
lopment of optimal therapeutics, although autophagy
can function both as a cytoprotective mechanism, but it
also has the capacity to cause cell death.Conclusion
This network analysis considering the established know-
ledge on different neurodegenerative dementia disease
represented by OMIM data and the drug targets in the
different phases of the drug discovery process, identifies
the autophagy process as a central dis-regulated pathway
in these sub-group of neurodegenerative disorders. We
could hypothesize that different mutation or alteration
at the genomic level could affect different phases of the
autophagy process and thus therapeutic modulation
could involve approaches that functionally target the
specific proteins. Exploring the molecular mechanisms
of autophagy opens an avenue for development of novel
drugs and particularly, these results could suggest the
potentiality of drug targeting specific PP2A subunits for
the treatment of dementia.Additional files
Additional file 1: Table S1. List of Drug targets, list of mediator
proteins in the dementia network, and gene ontology biological
functions enrichment analysis results of all mediators, mediator related to
tauopathies and highly ranked protein in the dementia network.
Additional file 2: Figure S2. Summary of statistically significant Gene
Ontology biological processes functional annotation corresponding to
proteins in the highly ranked proteins as obtained from REVIGO [28].
Nodes are GO terms and edges represent the strongest GO terms
pairwise similarity. Colors represent the p-values (low values in green,
high in red). Only significant GO terms are shown (P < 0.001).
Additional file 3: Table S3. List of 45 mediators (with their degree
centrality related to dementia and autophagy [29] networks) found in the
autophagy interaction network [29]. In bold are proteins that play a role
as the articulation points in the human autophagy network.
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pathway as described in the Biocarta database. In red are labeled the
dementia network mediator proteins.
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